





(PCT Article 18 and Rules 43 and 44)

Applicant' 03482.000	s or agent's file reference 10	FOR FURTHER ACTION	see Notific Report (Fo	ation of Transmittal of International Search orm PCT/ISA/220) as well as, where applicable, ow.
International application No. PCT/US03/25614		International filing date (day/mont 15 August 2003 (15.08.2003)	h/year)	(Earliest) Priority Date (day/month/year) 15 August 2002 (15.08.2002)
Applicant GENZYM	E CORPORATION			
applicant a	national search report consists	py is being transmitted to the Integrated of a total of sheets.	rnational l	
<u>_</u>	It is also accompanied	by a copy of each prior art docu	ment cited	l in this report.
a.	of the Report With regard to the language, a language in which it was filed,	the international search was carried unless otherwise indicated under the	out on the	basis of the international application in the
b.	Authority (Rule 23.1(b)). With regard to any nucleotide	and/or amino acid sequence discl		international application furnished to this international application, the international
\square	search was carried out on the			
contained in the international application in written form.				
filed together with the international application in computer readable form.				
H	furnished subsequently to this Authority in written form.			
H	furnished subsequently to this Authority in computer readable form.			
	the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.			
	the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.			
2.	Certain claims were found	unsearchable (See Box I).		
3. With	Unity of invention is lacking (See Box II).			
	regard to the title, the text is approved as subm	itted by the amplicant		
		by this Authority to read as follows	:	
5. With regard to the abstract, the text is approved as submitted by the applicant.				
	the text has been established, may, within one month from	according to Rule 38.2(b), by this the date of mailing of this internation	Authority a	is it appears in Box III. The applicant report, submit comments to this Authority.
6. The fi	gure of the drawings to be pub	lished with the abstract is Figure No)	
	as suggested by the applicant			None of the figures
	because the applicant failed t	o suggest a figure.		
	because this figure better cha			

Form PCT/ISA/210 (first sheet) (July 1998)

International application No.

PCT/US03/25614

	ational report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1.	Claim Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2.	Claim Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. 6.4(a)	Claim Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule
Box II C	bservations where unity of invention is lacking (Continuation of Item 2 of first sheet)
1 2	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite.
1.	
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-13 [drawn to delta(translocon-associated protein delta)]
2.	As all searchable claims. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-13 [drawn to delta(translocon-associated protein delta)]
2.	As all searchable claims. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-13 [drawn to delta(translocon-associated protein delta)]

Form PCT/ISA/210 (continuation of first sheet(1)) (July 1998)

International	application N	٧o.
---------------	---------------	-----

PCT/US03/25614

	The state of the s			
	IPC(7) : C12Q 1/00, 1/68, 1/70; G01N 33/53, 33/567, 33/569			
	US CL: 435/4, 5, 6, 7.1, 7.2, 7.21 According to International Patent Classification (IPC) or to both national classification and IPC			
	Minimum documentation searched (classification system followed by classification symbols) U.S.: 435/4, 5, 6, 7.1, 7.2, 7.21			
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet				
	UMENTS CONSIDERED TO BE RELEVANT			
Category *	Citation of document, with indication, where	appropriate, of the relevant passages	Relevant to claim No.	
Α	WANG, Z. ET AL. Cloning and molecular charac Monodelphis TRAP in ultraviolet B-induced melan Vol. 14, No. 2, pp. 107-114, entire document.	terization of a human ortholog of oma. Melonoma Research. April 2004,	1-13	
Α	MIYAZAKI, K. ET AL. NEDL1, a Novel Ubiquitin-protein Isopeptide Ligase for Dishevelled-1, Targets Mutant Superoxide Dismutase-1. The Journal of Biological Chemistry. 19 March 2004, Vol. 279, No. 12, pages 11327-11335, entire document.			
Α	BRENNER, V. ET AL. Genomic Organization of Two Novel Genes on Human Xq28: Compact Head to Head Arrangement of IDHgamma and TRAPdelta is Conserved in Rat and Mouse. Genomics. 15 August 1997, Vol. 44, No. 1, pages 8-14, entire document.			
A	KUNST, C.B. ET AL. Mutations in SOD1 associa cause novel protein interactions. Nature Genetics. 394, entire document.	ted with amyotrophic lateral sclerosis January 1997, Vol. 15, No. 1, pp. 91-	1-13	
	Further documents are listed in the continuation of Box C. See patent family annex.			
** Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent published on or after the international filing "X" document of particular relevance; the claimed invention can considered to involve an invention considered novel or cannot be considered to involve an invention.			ation but cited to understand invention claimed invention cannot be red to involve an inventive	
establish t	establish the publication date of another citation or other special reason (as specified) Considered to involve an inventive step when the document is combined with one or more other such documents, such con		claimed invention cannot be when the document is a documents, such combination	
O" document referring to an oral disclosure, use, exhibition or other means				
"E" document published prior to the international filing date but later than the				
Date of the actual completion of the international search Date of mailing of the international search report				
15 February 2005 (15.02.2005) 27 DEC 2005				
Mail Com P.O.	iling address of the ISA/US Stop PCT, Attn: ISA/US missioner for Patents Box 1450	Authorized officer J. Roberts for Christopher J Nichols, Ph.D.		
Alexandria, Virginia 22313-1450 Telephone No. (571) 273-1600 Facsimile No. (571) 273-3201				

Form PCT/ISA/210 (second sheet) (July 1998)

DOT	O LCOS	Incl !!	۰
P(. I	ハルハリン	/25614	

tegory *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
A	GIALLONGO, A. ET AL. Structural features of the human gene for muscle-specific enolase differential splicing in the 5'-untranslated sequence generates two forms of mRNA. Eur. J. Biochem. 1993, Vol. 214, pages 367-374, entire document.	1-13
	·	

PCT/US03/25614

INTERNATIONAL SEARCH REPORT

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group 1, claim(s) 1-13, drawn to a method to aid in diagnosing glioma comprising the steps of detecting an expression product.

Group 2, claim(s) 14-21, drawn to a method of treating a glioma comprising the steps of administering an antibody.

Group 3, claim(s) 22-35 and 47-60, drawn to a method of identifying a test compound as a potential anti-caner or anti-glioma drug.

Group 4, claim(s) 36-46, drawn to a method to aid in diagnosing glioma comprising the steps of detecting an mRNA.

Group 5, claim(s) 61-67, drawn to a method to induce an immune response to glioma.

This application contains claims directed to more than one species of the generic invention. These species are deemed to tack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1. The species listed do not share a common structure or function.

The following claim(s) are generic:

Group 1, Claim 1, all species listed therein.

Group 2, Claim 14, all species listed therein.

Group 3. Claims 22 and 47, all species listed therein in each claim.

Group 4, Claim 36, all species listed therein.

Group 5, Claim 61, all species listed therein.

In order for more than one species to be examined, the appropriate additional examination fees must be paid.

Applicant is invited to select one species per generic claim listed per group elected.

The inventions listed as Groups 1-5 do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Group 1 is drawn to the special technical feature of detecting an expression product, which is not shared by any of the other groups.

Group 2 is drawn to the special technical feature of administering an antibody, which is not shared by any of the other groups.

Group 3 is drawn to the special technical feature of identifying a test compound, which is not shared by any of the other groups.

Group 4 is drawn to the special technical feature of detecting an mRNA, which is not shared by any of the other groups.

Group 5 is drawn to the special technical feature of inducing an immune response, which is not shared by any of the other groups.

Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT	PCT/US03/25614
Continuation of B. FIELDS SEARCHED Item 3: WEST (USPT, PGPUBS, USOCR, JPO, EPO, DERWENT); NCBI (PUBME delta(translocon-associated protein delta); colorectal tumor, colon tumor, colo microarrays	ED); STN (BIOSCIENCE) in cancer, colorectal cancer, gene expression, ESTs.

Form PCT/ISA/210 (second sheet) (July 1998)